Encouraging Outcomes in Japan Phase III Trial of Acoramidis for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Consistent with Global ATTRibute-CM Phase III Trial Positive high-level results from the Japan Phase III trial…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in macular edema due to branch and central…
Biogen to Reallocate Resources for Alzheimer’s Disease Franchise Growth Strategy” Biogen Inc. (Nasdaq: BIIB) has unveiled plans to strategically reallocate resources in the Alzheimer’s disease (AD) therapeutic area to drive…
FDA Grants Fast Track Designation to BioNTech and DualityBio for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305 BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co., Ltd. (“DualityBio”) today announced that the U.S. Food…
Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) have announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for tisotumab vedotin, an antibody-drug conjugate…
Labcorp (NYSE: LH), a renowned provider of cutting-edge and all-encompassing laboratory services globally, has introduced and made accessible a recently FDA-cleared blood test. This test is designed for evaluating the…
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; referred to as “Shionogi”) has revealed that Pixie Dust Technologies, Inc. (Head Office: Tokyo, Japan; Representative…
Bio-Techne Corporation (NASDAQ: TECH) has released its financial results for the second quarter ending December 31, 2023. Key Highlights for the Second Quarter of Fiscal Year 2024: Bio-Techne’s financial statements…
Bio-Techne Corporation (NASDAQ: TECH) has unveiled a groundbreaking achievement, as its spatial biology brand, Advanced Cell Diagnostics (ACD), sets a new industry standard. The innovation comes in the form of…
Teva Announces Plan to Sell its Active-Pharmaceutical Ingredient (API) Business, ‘TAPI,’ as a Strategic Move Towards Growth Teva disclosed today its decision to divest its active-pharmaceutical ingredient (API) business, known…
Grifols, a distinguished global healthcare company with a 115-year legacy as a leading manufacturer of plasma-derived medicines, has bolstered its senior management team through two strategic appointments. Dr. Roland Wandeler…
Enhanced Precautions and Vigilance for Avian Influenza during Lunar New Year Celebrations in Asia As preparations for Lunar New Year festivities in Asia gain momentum, the increased trading and handling…